Ascentage Pharma Group International
AAPGVOTCHealthcare
$17.38
+$0.13(+0.75%)
Market Cap$127308500
P/E Ratio—
52W High$18.0
52W Low$16.5
Ascentage Pharma Group International (AAPGV) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AAPGV · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.98B | $0.22B | $0.21B | $0.03B | $0.01B |
| Cost of Revenue | $0.03B | $0.03B | $0.02B | $0.00B | $0.00B |
| Gross Profit | $0.95B | $0.19B | $0.19B | $0.02B | $0.01B |
| Gross Margin %(computed) | 97.03% | 86.24% | 89.51% | 88.08% | 84.21% |
| Operating Expenses | |||||
| R&D Expenses | $0.95B | $0.71B | $0.74B | $0.77B | $0.56B |
| G&A Expenses | $0.19B | $0.18B | $0.17B | $0.14B | $0.06B |
| Total Operating Expenses | $1.32B | $1.06B | $1.04B | $0.89B | $0.67B |
| Operating Income | ($0.37B) | ($0.87B) | ($0.85B) | ($0.87B) | ($0.66B) |
| Operating Margin %(computed) | -37.70% | -393.11% | -405.23% | — | — |
| Interest Income | $0.04B | $0.03B | $0.01B | $0.01B | $0.01B |
| Interest Expense | $0.06B | $0.10B | $0.05B | $0.02B | $0.01B |
| Income Before Tax | ($0.40B) | ($0.93B) | ($0.89B) | ($0.83B) | ($0.68B) |
| Income Tax Expense | $0.01B | ($0.01B) | ($0.00B) | ($0.05B) | $0.00B |
| Net Income | ($0.41B) | ($0.93B) | ($0.88B) | ($0.78B) | ($0.68B) |
| Net Margin %(computed) | -41.34% | -416.98% | -421.02% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.34 | $-13.12 | $-13.40 | $-12.28 | $-12.56 |
| Wtd Avg Shares | 0.08B | 0.07B | 0.07B | 0.06B | 0.05B |
| EBITDA | ($0.24B) | ($0.74B) | ($0.84B) | ($0.92B) | ($0.67B) |
| EBITDA Margin %(computed) | -24.23% | -334.98% | -398.64% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CNY · B
Explore more Ascentage Pharma Group International data
About Ascentage Pharma Group International (AAPGV) Income Statement
Ascentage Pharma Group International (AAPGV) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, AAPGV reported revenue of $0.98B, gross profit of $0.95B (gross margin 97.03%), and net income of ($0.41B) — a net profit margin of -41.34%.
Frequently asked questions
AAPGV · 4 questionsAscentage Pharma Group International (AAPGV) reported revenue of $0.98B for 2024, up 341.8% year-over-year.
AAPGV revenueAAPGV salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08